PF-Atlas › Clinical Trials › NCT04135495

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

ELX-02 · Phase 2

Registry ID

NCT04135495

Phase

Phase 2

Status

Completed

Drug / intervention

ELX-02

Sponsor

Eloxx Pharmaceuticals, Inc.

Start

2019-11-25

About this trial

ELX-02 is evaluated in NCT04135495, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Eloxx Pharmaceuticals, Inc.. Current status: Completed.

View NCT04135495 on ClinicalTrials.gov →

Explore related

All ELX-02 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT04135495 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.